Why Gemphire Is Tuesday’s Big Biotech Loser
Gemphire shares were more than halved on Tuesday after the company provided an update in regards to the clinical hold on gemcabene with respect to clinical trials of longer than six months in duration.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 126
Why Ovid Therapeutics Is Monday’s Big Biotech Loser
Ovid Therapeutics shares were crushed to start the week even though the company announced positive midstage results for its Angelman syndrome study.
Why Protagonist Therapeutics Is Getting a Second Chance
Protagonist Therapeutics shares saw a solid gain on Monday after the firm announced positive results from its midstage trial in patients with ulcerative colitis. This comes after some controversy within the study earlier this…
Eli Lilly to Spin Off Elanco in IPO
Animal health company Elanco Animal Health has filed with the SEC regarding its initial public offering.
Teva Just Can’t Seem to Get Earnings Right
Teva shares stumbled after it released its most recent quarterly results before the markets opened on Thursday.
Pfizer Gets the Script Flipped on It in Q2
Pfizer released better-than-expected second-quarter financial results before the markets opened on Tuesday.
What to Expect When Pfizer Reports Tuesday
Pfizer is scheduled to release its second-quarter financial results before the markets open on Tuesday.
Why Sienna Biopharmaceuticals Shares Are Stumbling
Sienna Biopharmaceuticals shares pulled back on Monday after the company announced less than favorable results from a couple of its acne trials.
Why RedHill Is Monday’s Big Biopharma Winner
RedHill Biopharma shares made a solid gain early on Monday after the firm announced positive results from its late-stage trial in Crohn’s disease.
Why AbbVie Earnings Were Not Enough for Investors
AbbVie released a better-than-expected quarterly report early on Friday, but shares retreated afterward.
Merck Underwhelms Despite Beating Earnings
Merck reported better-than-expected second-quarter results before the markets opened on Friday, but shares retreated afterward.
Should Celgene Be Getting More Love?
Celgene released better-than-expected quarterly results and updated guidance before the markets opened on Thursday.
Gilead Earnings Beat Not Enough For Investors
Gilead reported its most recent quarterly results after the markets closed on Wednesday. The major biotech posted $1.91 in earnings per share (EPS) and $5.65 billion in revenue, versus with consensus estimates that called…
What to Expect When Gilead Reports
Gilead is scheduled to release its second-quarter financial results after the markets close on Wednesday, and analyst expectations are low.
Major Pharma Stocks Scare Off Short Sellers
The July 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.